References
- Cancer in children and adolescents. National Cancer Institute. https://www.cancer.gov/types/childhood-cancers/child-adolescent-cancers-fact-sheet. Published November 10, 2021. Accessed January 23, 2022.
- Ward E, DeSantis C, Robbins A, Kohler B, Jemal A. Childhood and adolescent cancer statistics, 2014. CA Cancer J Clin. 2014;64(2):83–103. doi:10.3322/caac.21219.
- The National Children’s Cancer Society. The Economic Impact of Childhood Cancer. Published online November 30, 2018.
- Merrill CT, Nagamine M, Hambrick MM. Pediatric hospital stays for cancer 2005. Healthcare Cost and Utilization Project (HCUP) Statistical Briefs [Internet]. https://www.ncbi.nlm.nih.gov/books/NBK61974/?report=printable. Published online 2007.
- Childhood cancer fact library. https://cac2.org/interest-groups/awareness/childhood-cancer-fact-library/. Accessed February 26, 2022.
- Schmucker C, Schell LK, Portalupi S, et al. Extent of non-publication in cohorts of studies approved by research ethics committees or included in trial registries. PLoS One. 2014;9(12):e114023. doi:10.1371/journal.pone.0114023.
- Chalmers I, Glasziou P. Avoidable waste in the production and reporting of research evidence. Lancet. 2009;374(9683):86–89. doi:10.1016/S0140-6736(09)60329-9.
- Lièvre M, Ménard J, Bruckert E, et al. Premature discontinuation of clinical trial for reasons not related to efficacy, safety, or feasibility. BMJ. 2001;322(7286):603–605. doi:10.1136/bmj.322.7286.603.
- Psaty BM, Rennie D. Stopping medical research to save money: a broken pact with researchers and patients. JAMA. 2003;289(16):2128–2131. doi:10.1001/jama.289.16.2128.
- Briel M, Olu KK, von Elm E, et al. A systematic review of discontinued trials suggested that most reasons for recruitment failure were preventable. J Clin Epidemiol. 2016;80:8–15. doi:10.1016/j.jclinepi.2016.07.016.
- Deichmann RE, Krousel-Wood M, Breault J. Bioethics in practice: considerations for stopping a clinical trial early. Ochsner J. 2016;16(3):197–198.
- Pasquali SK, Lam WK, Chiswell K, Kemper AR, Li JS. Status of the pediatric clinical trials enterprise: an analysis of the US ClinicalTrials.gov registry. Pediatrics. 2012;130(5):e1269–e1277. doi:10.1542/peds.2011-3565.
- Ramachandran R, Morten CJ, Ross JS. Strengthening the FDA’s enforcement of ClinicalTrials.gov reporting requirements. JAMA. 2021;326(21):2131. Published online November doi:10.1001/jama.2021.19773.
- Office of the Commissioner. Notices of noncompliance and civil money penalty actions. https://www.fda.gov/science-research/fdas-role-clinicaltrialsgov-information/clinicaltrialsgov-notices-noncompliance-and-civil-money-penalty-actions. Published September 2, 2021. Accessed December 6, 2021.
- United States Office of the Federal Register. An Act, To Amend The Federal Food, Drug, and Cosmetic Act to Revise and Extend The User-Fee Programs for Prescription Drugs,… September 27, 2007, Public Law 110–85. 2008.
- Health and Human Services Department. Clinical trials registration and results information submission. Fed Reg. 2016;81:64981–65157. https://www.federalregister.gov/d/2016-22129
- Johnson AL, Fladie I, Anderson JM, Lewis DM, Mons BR, Vassar M. Rates of discontinuation and nonpublication of head and neck cancer randomized clinical trials. JAMA Otolaryngol Head Neck Surg. 2020;146(2):176. doi:10.1001/jamaoto.2019.3967.
- Pica N, Bourgeois F. Discontinuation and nonpublication of randomized clinical trials conducted in children. Pediatrics. 2016;138(3). doi:10.1542/peds.2016-0223.
- Traxler B, Walters C, Adewumi MT, Meyer C, Puckett M, Vassar M. An analysis of the rates of discontinuation and non-publication of colorectal cancer clinical trials. Int J Colorectal Dis. 2021;36(11):2529–2532. doi:10.1007/s00384-021-03972-0.
- Recap of FDA drug approvals in 2019. https://www.ahdbonline.com/web-exclusives/fda-approvals/2889-recap-of-fda-drug-approvals-in-2019. Published online January 8, 2020. Accessed June 29, 2022.
- Office of the Commissioner. Pediatric Oncology Drug Approvals. U.S. Food and Drug Administration. https://www.fda.gov/about-fda/oncology-center-excellence/pediatric-oncology-drug-approvals. Accessed June 29, 2022.
- Goodyear MDE, Krleza-Jeric K, Lemmens T. The Declaration of Helsinki. BMJ. 2007;335(7621):624–625. doi:10.1136/bmj.39339.610000.BE.